The first three calcitonin gene-related peptide (CGRP) inhibitors approved for prevention of migraine displayed a reassuring safety profile in real-world clinical practice during the first 6 months ...
AJOVY demonstrated efficacy and a consistent safety profile in the SPACE trial, making it the first and only calcitonin gene-related peptide ...
Most patients with migraine are women, and this observation is reflected in clinical studies. A pharmacologist and a neurologist from the United States argue that the efficacy of calcitonin ...
Six different injected or oral medicines that target the protein CGRP should be among the first drugs people try to prevent migraine, the American Headache Society advises. People with migraine should ...
Meloxicam/Rizatriptan Effective in Migraine Patients With Inadequate Response to Oral CGRP Inhibitor
Findings showed meloxicam/rizatriptan statistically significantly improved migraine treatment response compared with prior oral CGRP inhibitor treatment. Topline data were announced from a phase 3 ...
Please provide your email address to receive an email when new articles are posted on . A majority of patients had initial or sustained significant symptom improvement, with few adverse effects. Most ...
Calcitonin gene-related peptide (CGRP) inhibitors -- a group of drugs commonly used to treat migraine -- were associated with decreased rates of acne and rosacea compared with drugs that did not ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback